Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349094 | 0.79 | HSP90AA1 (0.35) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL23235334 | 0.79 | GRM5 (0.31) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL14299556 | 0.79 | GRM5 (0.31) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2515112 | 0.79 | GRM5 (0.34) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2160719 | 0.78 | GRM5 (0.50) | GRM5 | |
| SCHEMBL3680715 | 0.76 | ACACB (0.34) | — | |
| SCHEMBL2974303 | 0.76 | GRM5 (0.58) | GRM5 | |
| SCHEMBL2284491 | 0.76 | KDM4E (0.33) | — | |
| SCHEMBL503751 | 0.76 | CYP1A2 (0.55) | GRM5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15903075 | 0.76 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| CN-102227431-A | Indole and indoline derivatives and methods of use thereof | ABBOTT LAB | 2011-10-26 | — | — | CN | disclosed |
| US-7989620-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| EP-2344505-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011008312-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010036998-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-01 | — | — | WO | disclosed |
| US-7648992-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2010-01-19 | — | — | US | disclosed |
| EP-1778673-B1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | ASTRAZENECA AB (SE) | 2009-11-11 | — | — | EP | disclosed |
| CN-100543024-C | The hydantoin derivatives that is used for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2009-09-23 | — | — | CN | disclosed |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| CN-1980914-A | Novel hydantoin derivatives for the treatment of obstructive airway diseases. | ASTRAZENECA AB (SE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1778673-A1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006004532-A1 | NOVEL HYDANTOIN DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE AIRWAY DISEASES | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | GRM5 778/4885GABRA1 3964/4885GABRG2 4252/4885 |
| US-20080064710-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | GRM5 2437/4885GABRA1 3102/4885GABRG2 4057/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | GRM5 778/4885GABRA1 3964/4885GABRG2 4252/4885 |
| US-20100144771-A1 | Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases | HRH4, HRH1, HRH2 | GRM5 2364/4885GABRA1 3061/4885GABRG2 4008/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | GRM5 778/4885GABRA1 3964/4885GABRG2 4252/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | GRM5 778/4885GABRA1 3964/4885GABRG2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.